371 related articles for article (PubMed ID: 21728912)
41. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
42. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab.
Murthy R; Eng C; Krishnan S; Madoff DC; Habbu A; Canet S; Hicks ME
J Vasc Interv Radiol; 2007 Dec; 18(12):1588-91. PubMed ID: 18057297
[TBL] [Abstract][Full Text] [Related]
43. Ethics for end-of-life treatments: metastatic colorectal cancer is one example.
Garattini L; van de Vooren K; Zaniboni A
Health Policy; 2013 Jan; 109(1):97-103. PubMed ID: 22981776
[TBL] [Abstract][Full Text] [Related]
44. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
[TBL] [Abstract][Full Text] [Related]
46. The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit.
Samelis GF; Ekmektzoglou KA; Tsiakou A; Konstadoulakis M
Hepatogastroenterology; 2011; 58(112):1968-71. PubMed ID: 22024069
[TBL] [Abstract][Full Text] [Related]
47. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
48. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
49. [Current status and perspectives of biologics in the treatment of metastatic colorectal cancer].
Takiuchi H
Nihon Rinsho; 2010 Oct; 68(10):1866-70. PubMed ID: 20954331
[TBL] [Abstract][Full Text] [Related]
50. Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer.
Kim JC; Kim SY; Cho DH; Ha YJ; Choi EY; Kim CW; Roh SA; Kim TW; Ju H; Kim YS
Clin Cancer Res; 2011 Mar; 17(5):1200-9. PubMed ID: 21239504
[TBL] [Abstract][Full Text] [Related]
51. [Outcomes of cetuximab combination chemotherapy in clinical practice for patients with metastatic colorectal cancer].
Yamazaki T; Iwaya A; Katayanagi N
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2529-33. PubMed ID: 24335364
[TBL] [Abstract][Full Text] [Related]
52. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
53. Bevacizumab: a review of its use in metastatic colorectal cancer.
McCormack PL; Keam SJ
Drugs; 2008; 68(4):487-506. PubMed ID: 18318567
[TBL] [Abstract][Full Text] [Related]
54. Use of monoclonal antibodies for metastatic colorectal cancer in the Andalusian public health system.
Santos-Ramos B; Fernández-Fernández R; Marín-Gil R; Espinosa-Bosch M; Peiró-Moreno S; Pérez-Guerrero C; Bautista-Paloma J
Int J Clin Pharm; 2013 Aug; 35(4):550-3. PubMed ID: 23673655
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
[TBL] [Abstract][Full Text] [Related]
56. [Use of antibodies for colorectal cancer chemotherapy].
Kanemitsu K; Kakeji Y
Nihon Rinsho; 2014 Jan; 72(1):114-9. PubMed ID: 24597358
[TBL] [Abstract][Full Text] [Related]
57. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
[TBL] [Abstract][Full Text] [Related]
58. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
Nygren P; Sørbye H; Osterlund P; Pfeiffer P
Acta Oncol; 2005; 44(3):203-17. PubMed ID: 16076691
[TBL] [Abstract][Full Text] [Related]
59. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
[TBL] [Abstract][Full Text] [Related]
60. A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.
Huang WT; Chen HH; Yeh CH; Lu YC; Hwang WS; Huang JS; Chen CP; Lin PC; Uen WC; Lee YC; Wang HM; Wu HC; Chen JS; Kao RH; Huang CC; Jeng HH; Lin CJ; Hsieh RK
J Investig Med; 2013 Oct; 61(7):1108-14. PubMed ID: 24013526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
